| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802981503017 | 298150301 | XEPLION INJ.SU.PRO 75MG/PF.SYR BTx1PF.SYRx75MG +2 βελόνες +2 βελόνες | 206.04 | 209.13 | 248.28 |
| 05/2018 | 2802981504014 | 298150401 | XEPLION INJ.SU.PRO 100MG/PF.SYR BTx1PF.SYRx100MG +2 βελόνες +2 βελόνες | 253.62 | 257.42 | 305.61 |
| 05/2018 | 2802981505011 | 298150501 | XEPLION INJ.SU.PRO 150MG/PF.SYR BTx1PF.SYRx150MG +2 βελόνες +2 βελόνες | 380.08 | 385.78 | 449.82 |
For the treatment of schizophrenia.
Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.
The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
The terminal elimination half-life of paliperidone is approximately 23 hours.
One week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as metabolites, and 6% – 12% of the dose was not recovered.
* 487 L